A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Albiglutide (Primary)
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jan 2013 Planned End Date changed from 1 Nov 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov record.